First-Generation TRK Inhibitors: Clinical Evidence and Indications - a podcast by Clinical Care Options
from 2021-10-15T20:15
In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC. Topics include:
- Basket trials leading to FDA approvals of larotrectinib and entrectinib
- Current pan-tumor indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors as well as ROS1-positive NSCLC
- Sequencing treatment with TRK inhibition in patients with solid tumors
- Clinically relevant similarities and differences between larotrectinib and entrectinib
Presenters:
George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York
Link to full program, including downloadable slidesets:
https://bit.ly/2YFIPfr
Further episodes of CCO Oncology Podcast
Further podcasts by Clinical Care Options
Website of Clinical Care Options